234 related articles for article (PubMed ID: 24398473)
1. Inducible nitric oxide synthase drives mTOR pathway activation and proliferation of human melanoma by reversible nitrosylation of TSC2.
Lopez-Rivera E; Jayaraman P; Parikh F; Davies MA; Ekmekcioglu S; Izadmehr S; Milton DR; Chipuk JE; Grimm EA; Estrada Y; Aguirre-Ghiso J; Sikora AG
Cancer Res; 2014 Feb; 74(4):1067-78. PubMed ID: 24398473
[TBL] [Abstract][Full Text] [Related]
2. Insulin like growth factor-1-induced phosphorylation and altered distribution of tuberous sclerosis complex (TSC)1/TSC2 in C2C12 myotubes.
Miyazaki M; McCarthy JJ; Esser KA
FEBS J; 2010 May; 277(9):2180-91. PubMed ID: 20412061
[TBL] [Abstract][Full Text] [Related]
3. mTORC2 is required for proliferation and survival of TSC2-null cells.
Goncharova EA; Goncharov DA; Li H; Pimtong W; Lu S; Khavin I; Krymskaya VP
Mol Cell Biol; 2011 Jun; 31(12):2484-98. PubMed ID: 21482669
[TBL] [Abstract][Full Text] [Related]
4. Involvement of TSC genes and differential expression of other members of the mTOR signaling pathway in oral squamous cell carcinoma.
Chakraborty S; Mohiyuddin SM; Gopinath KS; Kumar A
BMC Cancer; 2008 Jun; 8():163. PubMed ID: 18538015
[TBL] [Abstract][Full Text] [Related]
5. Enhanced expression of glucose transporter-1 in vascular smooth muscle cells via the Akt/tuberous sclerosis complex subunit 2 (TSC2)/mammalian target of rapamycin (mTOR)/ribosomal S6 protein kinase (S6K) pathway in experimental renal failure.
Lin CY; Hsu SC; Lee HS; Lin SH; Tsai CS; Huang SM; Shih CC; Hsu YJ
J Vasc Surg; 2013 Feb; 57(2):475-85. PubMed ID: 23265586
[TBL] [Abstract][Full Text] [Related]
6. Critical role of arachidonic acid-activated mTOR signaling in breast carcinogenesis and angiogenesis.
Wen ZH; Su YC; Lai PL; Zhang Y; Xu YF; Zhao A; Yao GY; Jia CH; Lin J; Xu S; Wang L; Wang XK; Liu AL; Jiang Y; Dai YF; Bai XC
Oncogene; 2013 Jan; 32(2):160-70. PubMed ID: 22349822
[TBL] [Abstract][Full Text] [Related]
7. Regulation of B-Raf kinase activity by tuberin and Rheb is mammalian target of rapamycin (mTOR)-independent.
Karbowniczek M; Cash T; Cheung M; Robertson GP; Astrinidis A; Henske EP
J Biol Chem; 2004 Jul; 279(29):29930-7. PubMed ID: 15150271
[TBL] [Abstract][Full Text] [Related]
8. Interferon beta augments tuberous sclerosis complex 2 (TSC2)-dependent inhibition of TSC2-null ELT3 and human lymphangioleiomyomatosis-derived cell proliferation.
Goncharova EA; Goncharov DA; Chisolm A; Spaits MS; Lim PN; Cesarone G; Khavin I; Tliba O; Amrani Y; Panettieri RA; Krymskaya VP
Mol Pharmacol; 2008 Mar; 73(3):778-88. PubMed ID: 18094073
[TBL] [Abstract][Full Text] [Related]
9. Rhebbing up mTOR: new insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis.
Kwiatkowski DJ
Cancer Biol Ther; 2003; 2(5):471-6. PubMed ID: 14614311
[TBL] [Abstract][Full Text] [Related]
10. Tuberous sclerosis complex activity is required to control neuronal stress responses in an mTOR-dependent manner.
Di Nardo A; Kramvis I; Cho N; Sadowski A; Meikle L; Kwiatkowski DJ; Sahin M
J Neurosci; 2009 May; 29(18):5926-37. PubMed ID: 19420259
[TBL] [Abstract][Full Text] [Related]
11. Identification of mechanically regulated phosphorylation sites on tuberin (TSC2) that control mechanistic target of rapamycin (mTOR) signaling.
Jacobs BL; McNally RM; Kim KJ; Blanco R; Privett RE; You JS; Hornberger TA
J Biol Chem; 2017 Apr; 292(17):6987-6997. PubMed ID: 28289099
[TBL] [Abstract][Full Text] [Related]
12. Estrogen-induced activation of mammalian target of rapamycin is mediated via tuberin and the small GTPase Ras homologue enriched in brain.
Yu J; Henske EP
Cancer Res; 2006 Oct; 66(19):9461-6. PubMed ID: 17018601
[TBL] [Abstract][Full Text] [Related]
13. Positive feedback regulation of human inducible nitric-oxide synthase expression by Ras protein S-nitrosylation.
Lee M; Choy JC
J Biol Chem; 2013 May; 288(22):15677-86. PubMed ID: 23599434
[TBL] [Abstract][Full Text] [Related]
14. Tuberous-sclerosis complex-related cell signaling in the pathogenesis of lung cancer.
Fuchs A; König K; Heukamp LC; Fassunke J; Kirfel J; Huss S; Becker AJ; Büttner R; Majores M
Diagn Pathol; 2014 Mar; 9():48. PubMed ID: 24593867
[TBL] [Abstract][Full Text] [Related]
15. The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stresses.
Smith EM; Finn SG; Tee AR; Browne GJ; Proud CG
J Biol Chem; 2005 May; 280(19):18717-27. PubMed ID: 15772076
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model.
Mi R; Ma J; Zhang D; Li L; Zhang H
J Genet Genomics; 2009 Jun; 36(6):355-61. PubMed ID: 19539245
[TBL] [Abstract][Full Text] [Related]
17. TSC2: filling the GAP in the mTOR signaling pathway.
Li Y; Corradetti MN; Inoki K; Guan KL
Trends Biochem Sci; 2004 Jan; 29(1):32-8. PubMed ID: 14729330
[TBL] [Abstract][Full Text] [Related]
18. Phospholipase D1 is an effector of Rheb in the mTOR pathway.
Sun Y; Fang Y; Yoon MS; Zhang C; Roccio M; Zwartkruis FJ; Armstrong M; Brown HA; Chen J
Proc Natl Acad Sci U S A; 2008 Jun; 105(24):8286-91. PubMed ID: 18550814
[TBL] [Abstract][Full Text] [Related]
19. Neurofibromatosis-1 regulates mTOR-mediated astrocyte growth and glioma formation in a TSC/Rheb-independent manner.
Banerjee S; Crouse NR; Emnett RJ; Gianino SM; Gutmann DH
Proc Natl Acad Sci U S A; 2011 Sep; 108(38):15996-6001. PubMed ID: 21896734
[TBL] [Abstract][Full Text] [Related]
20. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2.
Garami A; Zwartkruis FJ; Nobukuni T; Joaquin M; Roccio M; Stocker H; Kozma SC; Hafen E; Bos JL; Thomas G
Mol Cell; 2003 Jun; 11(6):1457-66. PubMed ID: 12820960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
